NBC News Story Quotes Former NFL Player That “There Is a Shift Happening” With the NFL’s Anti-Cannabis Policy, NBC Report Cites New NFLPA Committee
SAN DIEGO, CA–(Marketwired – November 22, 2016) – Medical Marijuana, Inc. (OTC PINK: MJNA) is pleased to announce that a new report from NBC 7’s “Football Night” features an interview with the Company’s CEO Dr. Stuart Titus discussing new research about cannabis and concussions, along with a testimonial from a former NFL player.
The NBC News report mentioned the NFL’s recent move to hire a new Chief Medical Officer to handle sports-related concussions and traumatic brain injury, and also a new committee appointed by the NFL Players Association to evaluate the potential for cannabis and marijuana to alleviate pain from sports-related injuries.
“These cannabinoids actually act as a second football helmet that is always with you,” the NBC 7 report quoted Dr. Titus as saying. “There has been some great research out of UCLA Medical Center of Torrance, they looked at 450 young adults who unfortunately were in traumatic brain injury situations; and of the ones who were in these traumatic brain injury situations, the ones who were regular cannabis users were 80 percent more likely to survive a traumatic brain injury — and this is presumably because they had this ‘second football helmet’ effect with them at all times.”
[SEE ALSO: The American Surgeon | National Institutes of Health (NIH)]
Other facts about Chronic Traumatic Encephalopathy (or CTE):
- A recent study shows that 96% of former NFL players tested positive for CTE
- The Concussion Foundation shows that 91% of ex-college football players have CTE
- Nearly 4 million suffer concussions as a result of sports and recreational activities each year
- CTE has been linked to dementia, depression and suicide; and
- There is currently no effective treatment for CTE
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.
Public Relations Contact:
Chief Executive Officer
Corporate Business Contact:
Nicholas R. Massalas
Director of Business Development
Medical Marijuana, Inc.
OTC Symbol: MJNA
Toll Free: 888-OTC- MJNA (888-682- 6562)
Investor Relations Contact:
Toll Free: (877) 964.6463
Office/Direct: (858) 264-6500
Email: [email protected]